LABETALOL Drug Study
LABETALOL Drug Study
LABETALOL Drug Study
GI: Elevated
Drug classification: liver function
Pharmacotherapeutics: Alpha- test results,
beta-adrenergic blocker. hepatic
Clinical: Antihypertensive. necrosis,
hepatitis,
indigestion,
nausea,
vomiting.
GU:
Ejaculation
failure,
impotence.
RESP:
Dyspnea,
wheezing
SKIN:
Jaundice,
pruritus, rash,
scalp tingling
Nursing Consideration:
During I.V. labetalol use, monitor blood pressure according to facility policy, usually every 5 minutes for 30 minutes, then
every 30 minutes for 2 hours, and then every hour for 6 hours.
Keep patient in supine position for 3 hours after I.V. administration.
Warning, be aware that labetalol masks common signs of shock.
Monitor blood glucose level in diabetic patient because labetalol may conceal symptoms of hypoglycemia.
Be aware that stopping labetalol tablets abruptly after long-term therapy could result in angina, MI, or ventricular
arrhythmias. Expect to taper dosage over 2 weeks while monitoring response.
Patient Teaching
Advise patient to report confusion, difficulty breathing, rash, slow pulse, and swelling in arms or legs.
Caution patient not to stop drug abruptly because doing so could cause angina and rebound hypertension.
Suggest that patient minimize effects of orthostatic hypotension by rising slowly, avoiding sudden position changes, and
taking labetalol at bedtime, if approved by the physician.
Instruct diabetic patient to check blood glucose level often and to be alert for signs and symptoms of hypoglycemia.
Inform patient that scalp tingling may occur early in treatment but is transient.
Urge patient to avoid alcohol during labetalol therapy.
Advise patient to inform eye healthcare provider if he needs cataract surgery because intraoperative floppy iris syndrome
has occurred during cataract surgery in some patients treated with the class of drugs of which labetalol is a member.